Core Insights - Wall Street anticipates a year-over-year decline in earnings for NewAmsterdam Pharma Company N.V. (NAMS) due to lower revenues, with a consensus expectation of a quarterly loss of $0.38 per share, reflecting a -111.1% change from the previous year [1][3] - Revenues are projected to be $3.88 million, which is an 86.7% decrease compared to the same quarter last year [3] - The stock's price movement will largely depend on how actual results compare to these estimates, with a potential for upward movement if results exceed expectations [2] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.95% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for NewAmsterdam Pharma is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +19.13%, suggesting a likelihood of beating the consensus EPS estimate [12] Earnings Surprise History - In the last reported quarter, NewAmsterdam Pharma was expected to post a loss of $0.52 per share but actually reported a loss of -$0.15, resulting in a positive surprise of +71.15% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Drugs industry, Corcept Therapeutics is expected to report earnings of $0.18 per share, indicating a year-over-year decline of -56.1%, with revenues expected to be $219.18 million, up 20.1% from the previous year [19] - Corcept's consensus EPS estimate has been revised down by 9.7% over the last 30 days, and it has a negative Earnings ESP of -72.60%, combined with a Zacks Rank of 5 (Strong Sell), making it challenging to predict an earnings beat [20]

Core Insights - Praxis Precision Medicines, Inc. (PRAX) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025 [1][3] - The consensus EPS estimate for the upcoming report is a loss of $3.45 per share, reflecting a 25.5% decrease year-over-year, while revenues are expected to be $0.33 million, up 10% from the previous year [3] Earnings Expectations - The earnings report could lead to a stock price increase if the actual results exceed expectations; conversely, missing estimates may result in a stock price decline [2] - The consensus EPS estimate has been revised down by 0.5% over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Praxis Precision Medicines is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.35%, suggesting a bullish outlook from analysts [12] - The stock currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Praxis Precision Medicines was expected to post a loss of $3.4 per share but actually reported a loss of -$3.31, achieving a surprise of +2.65% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - PTC Therapeutics (PTCT), another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.19 per share for the same quarter, which represents a year-over-year increase of 14.4% [18] - PTC Therapeutics has an Earnings ESP of +5.75% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Perrigo despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Perrigo is expected to report quarterly earnings of $0.75 per share, reflecting a year-over-year decrease of 7.4%, while revenues are projected to be $1.1 billion, an increase of 0.8% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.92% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Perrigo is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.33%, suggesting bearish sentiment among analysts [12]. Historical Performance - In the last reported quarter, Perrigo was expected to earn $0.59 per share but only achieved $0.57, resulting in a surprise of -3.39%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13][14]. Investment Considerations - Despite the negative Earnings ESP and Zacks Rank of 4, which complicates predictions for an earnings beat, investors are advised to consider other factors before making investment decisions [12][17].

Core Viewpoint - Wall Street anticipates flat earnings for Performance Food Group (PFGC) compared to the previous year, with a focus on revenue growth impacting stock price [1][3] Earnings Expectations - The upcoming earnings report is expected to show earnings of $1.16 per share, unchanged from the year-ago quarter, with revenues projected at $16.87 billion, reflecting a 9.4% increase [3] - A positive stock movement is likely if actual results exceed these expectations, while a miss could lead to a decline [2] Estimate Revisions - The consensus EPS estimate has been revised down by 1.5% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Performance Food is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +3.58% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive reading indicates a likely earnings beat, especially when combined with a Zacks Rank of 2 [10][12] - Historical performance shows that Performance Food has beaten consensus EPS estimates only once in the last four quarters, with a recent surprise of +6.90% [13][14] Conclusion - Performance Food is positioned as a strong candidate for an earnings beat, but investors should consider additional factors before making investment decisions [17]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Quantum Computing Inc. (QUBT) despite flat revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.05 per share, reflecting a year-over-year change of +16.7%, with revenues projected at $0.1 million, unchanged from the previous year [3]. - The consensus EPS estimate has been revised 16.67% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate insights [8]. - Quantum Computing Inc. has an Earnings ESP of 0%, indicating no recent differing analyst views from the consensus estimate, and currently holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Quantum Computing Inc. was expected to post a loss of $0.06 per share and delivered exactly that, resulting in no surprise [14]. - The company has not beaten consensus EPS estimates in any of the last four quarters [15]. Conclusion - Quantum Computing Inc. does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of its earnings release [18].

Core Viewpoint - Acadia Healthcare (ACHC) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for November 5, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The consensus estimate for quarterly earnings is $0.72 per share, reflecting a year-over-year decrease of 20.9%, while revenues are projected to be $853.31 million, representing a 4.6% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 1.73% higher, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Acadia Healthcare is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.79%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with positive readings being more reliable [9][10]. - Acadia Healthcare currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Acadia Healthcare was expected to post earnings of $0.71 per share but achieved $0.83, resulting in a surprise of +16.90% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Acadia Healthcare does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of the earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Acadia Pharmaceuticals despite higher revenues, with actual results being crucial for stock price movement [1][2]. Financial Expectations - Acadia is expected to report quarterly earnings of $0.14 per share, reflecting a -30% change year-over-year, while revenues are projected at $273.59 million, an increase of 9.3% from the previous year [3]. - The consensus EPS estimate has been revised 1.77% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that Acadia's Most Accurate Estimate is lower than the consensus estimate, resulting in an Earnings ESP of -19.33%, suggesting bearish sentiment among analysts [12]. - Despite the negative Earnings ESP, Acadia holds a Zacks Rank of 2, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Acadia exceeded expectations by delivering earnings of $0.16 per share against an expected $0.14, resulting in a surprise of +14.29% [13]. - Over the past four quarters, Acadia has beaten consensus EPS estimates three times [14]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, Amgen is expected to report earnings of $5 per share, indicating a -10.4% year-over-year change, with revenues projected at $8.94 billion, up 5.2% [18][19]. - Amgen's consensus EPS estimate has been revised down by 0.9% in the last 30 days, leading to an Earnings ESP of -1.25% and a Zacks Rank of 3, making predictions of an earnings beat challenging [19][20].

Core Viewpoint - The market anticipates Alector (ALEC) will report a year-over-year increase in earnings despite lower revenues, with actual results being crucial for stock price movement [1][2]. Company Summary - Alector is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year change of +2.3% [3]. - Revenues are projected to be $2.63 million, down 82.9% from the same quarter last year [3]. - The consensus EPS estimate has been revised 3.13% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that Alector's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.77% [12]. - Alector currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Alector was expected to post a loss of $0.45 per share but actually reported a loss of -$0.30, achieving a surprise of +33.33% [13]. - Over the past four quarters, Alector has beaten consensus EPS estimates four times [14]. Industry Context - Another company in the same industry, AC Immune (ACIU), is expected to report a loss of $0.22 per share, indicating a year-over-year change of -466.7% [18]. - AC Immune's revenues are expected to be $1.52 million, down 94.8% from the previous year [18]. - The consensus EPS estimate for AC Immune has been revised 4.3% higher in the last 30 days, but it also has a negative Earnings ESP of -4.55% [19][20].

Core Viewpoint - Jack Henry (JKHY) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on November 4, with a consensus estimate of quarterly earnings at $1.64 per share, reflecting a year-over-year change of +0.6%. Revenues are projected to be $636.69 million, an increase of 5.9% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.87%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Jack Henry is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.42%, suggesting a bearish outlook from analysts [12]. Historical Performance - In the last reported quarter, Jack Henry exceeded the expected earnings of $1.46 per share by delivering $1.75, resulting in a surprise of +19.86%. The company has beaten consensus EPS estimates in the last four quarters [13][14]. Investment Considerations - Despite the potential for an earnings beat, the combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive outcome for the upcoming earnings report [12][17].

Company Overview - Ultragenyx (RARE) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $1.23 per share, reflecting a +12.1% change from the previous year [1][3] - Revenues are anticipated to reach $167.55 million, representing a 20.1% increase compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 0.43% lower over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Ultragenyx is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.47%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Ultragenyx was expected to post a loss of $1.27 per share but actually reported a loss of -$1.17, achieving a surprise of +7.87% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is expected to report earnings of $4.55 per share for the same quarter, indicating a year-over-year change of +3.9% and revenues of $3.04 billion, up 9.7% from the previous year [18][19] - Vertex has an Earnings ESP of +0.57% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [19][20]